Abstract: Objective Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that
failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy".
For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO
guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we
reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.